Hi team
IMO, thinking critically, I think it is far, far more likely that the ann is concerning a big pharma takeover bid, instead of Incannex planning to acquire a smaller company. Biotechs rarely acquire smaller companies especially when they run so lean and prioritise clinical progression of existing assets. Doubly so when said assets are as high-potential as the ones IHL has in development.
The company does not have the cash to acquire a fair dinkum asset that can stand on the same level as the current drugs, IMO. Not to mention, the cash should be used to clinically progress the existing assets.
Combine that with the PR firm and Jazzy Joel going on patrol in the US, and I think that this is more likely due to big names giving the IHL-42x results the attention it deserved.
- Forums
- ASX - By Stock
- Ann: Trading Halt
Hi teamIMO, thinking critically, I think it is far, far more...
-
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online